Year: 2025

Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems  Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% PDF Version AUSTIN, Texas, January 13, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024. The Company experienced robust demand for its Focal One Robotic HIFU technology, reporting preliminary record fourth quarter of 11 Focal One Systems. “Our strong fourth quarter performance reflects the growing adoption of our industry-leading Focal One Robotic HIFU technology platform, which is fundamentally transforming how urologists manage prostate cancer,”...

Ten Atlanta Braves Spring Training Games will be Available for Fans to Watch on Gray Media Network of Stations in 2025 ATLANTA, Jan. 13, 2025 (GLOBE NEWSWIRE) — Atlanta Braves fans will be able to watch more Spring Training action than ever before as the team makes ten Spring training games available across two dozen Gray Media stations, beginning with the February 27 game versus the Washington Nationals. As part of the Braves’ new partnership with Gray Media announced last month, the ten Spring Training games will be exclusively broadcast on local television stations in 24 markets across the Southeast. The Gray schedule includes the second annual Major League Baseball Spring Breakout game, which will feature top prospects from the Braves and the Detroit Tigers on March 16. The Gray Media broadcast schedule for Spring 2025 is...

More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Anticipated to Commence in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Underway, with Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Cash Runway Expected to Support Operating Plans into 2027, Now Inclusive of Commercial Readiness Activities for BEAM-101 Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today...

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Completed two financings totaling $135 million in combined gross proceeds, with funds expected to support operations through end of 2026 IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq:...

LONDON, Ontario, Jan. 13, 2025 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced the Company will ring the closing bell at the Nasdaq MarketSite in Times Square, New York, on Friday, January 17, 2025. This event marks a significant milestone for Aduro following its recent uplisting to the Nasdaq Capital Market. The ceremony will be led by Ofer Vicus, CEO of Aduro, accompanied by members of the Company’s leadership team, Board of Directors, employees, and key stakeholders who have been instrumental in supporting Aduro’s journey. The live broadcast of the Nasdaq Closing...

MONTREAL, Jan. 13, 2025 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY.A; RAY.B) will release its financial results for the third quarter ended December 31, 2024, on Tuesday, February 4, 2025, after the markets close. Management will hold a conference call to discuss the financial results the next day, February 5, 2025, at 10:00 a.m. Eastern Time. Details of the Conference Call Via the internet at www.corporate.stingray.com Via telephone: (+1) 800-717-1738, Montreal (+1) 514-400-3792, Toronto (+1) 289-514-5100 or New York (+1) 646-307-1865 Conference Call Rebroadcast A rebroadcast of the conference call will be available until midnight, March 5, 2025, by dialing (+1) 888-660-6264, Toronto (+1) 289-819-1325 or New York (+1) 646-517-3975 and entering passcode 97537. About Stingray Stingray (TSX: RAY.A; RAY.B), a global music, media,...

New service will address a significant market opportunity and grant new flexibility to women seeking reproductive flexibility BANGKOK, Jan. 13, 2025 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced the launch of its innovative lifetime egg freezing service in Asia. The innovative “one charge, no worries” fertility preservation solution is designed to serve the growing needs of women across Asia, and will allow customers to make a one-time payment to arrange for lifetime egg freezing. NewGen’s new service addresses a robust market opportunity, particularly in light of increasing demand for egg freezing services in the region. The global egg freezing and embryo...

After nearly 38 years with Jyske Bank – of these almost 16 years on the Group Executive Board – Niels Erik Jakobsen, Managing Director, has decided to retire in the course of the second quarter of 2025. Niels Erik Jakobsen was employed by Jyske Bank on 1 August 1987. He joined the Group Executive Board on 1 September 2009 and has been in charge of e.g. Capital Markets and most recently Personal Clients and Wealth Management. In addition, Niels Erik Jakobsen is Chairman of the Supervisory Boards of Jyske Bank’s subsidiaries Jyske Realkredit and Jyske Finans and on the Boards of BankInvest and Letpension. Kurt Bligaard Pedersen, Chairman of the Supervisory Board of Jyske Bank, states: ”Niels Erik Jakobsen has made a significant mark on Jyske Bank’s development over the years, and with his considerable knowledge and insight, especially...